Celecoxib is the inhibitor of cyclooxygenase-2 (COX-2) and was reported to enhance the antitumor effects of chemotherapy and radiotherapy for ESCC (Yusup et al., 2014; Kim and Shah, 2017). Here, PTGS2 is linked to esophageal squamous cell carcinoma.